Klotho

Discovered in 1997 by Dr. Makoto Kuro-o, the protein Klotho has over two decades of preclinical evidence from rodent models supporting its roles in longevity, cognitive function, and kidney health. Klotho itself is an endogenous transmembrane protein encoded by the KL gene; a cleaved, soluble form called alpha-klotho circulates in plasma and acts as a hormone. As of 2026, two independent Phase 1 trials in humans had been initiated to test its effects. No klotho-based therapy is approved for any indication.

Discovery and Basic Biology

Klotho was identified by Kuro-o and colleagues in Nature in 1997 when they characterized a mouse mutant with a phenotype resembling premature aging. The mutant mice showed short lifespan, vascular calcification, osteopenia, sarcopenia, skin atrophy, infertility, and pulmonary emphysema. Positional cloning identified the responsible gene, which they named klotho after the Greek goddess of fate.

The KL gene encodes a 130 kDa single-pass transmembrane protein with two extracellular domains (KL1 and KL2) that resemble beta-glucosidases. Two physiological forms exist:

• Membrane-bound klotho, expressed primarily in kidney distal convoluted tubule and choroid plexus cells, acts as an obligate co-receptor for FGF23 (fibroblast growth factor 23). The klotho-FGF23 complex regulates phosphate excretion, 1,25-dihydroxyvitamin D synthesis, and calcium homeostasis.
• Soluble alpha-klotho, generated by proteolytic cleavage of the extracellular domain, circulates in blood and acts as a hormone with effects far from its tissue of origin, particularly on brain function and cellular signaling.

Plasma alpha-klotho concentrations are highest in childhood, peak in young adulthood, and decline approximately linearly with age. By age 80, levels are typically 50 to 60 percent of young-adult values. The decline is faster in people with chronic kidney disease, in whom klotho deficiency contributes to the cardiovascular and bone complications of CKD.

Rodent Longevity and Aging Data

The mouse data, accumulated over two decades, is the basis for the entire human translation effort:

• Klotho-knockout mice show accelerated aging and live approximately 8 to 9 weeks (vs ~2 years for wild-type)
• Klotho-overexpressing mice live approximately 20 to 30 percent longer than wild-type controls
• Klotho gene therapy delivered to adult mice extends lifespan by approximately 20 percent and improves age-related decline in bone, muscle, and brain function
• Recombinant klotho injection in aged mice improves synaptic plasticity, spatial memory, and resilience to neurodegenerative stress

The cognitive effects have been studied extensively by Dr. Dena Dubal's group at UCSF and others. A single low-dose injection of klotho enhances cognition in young and aged mice. The effect appears to depend on enhanced NMDA receptor signaling through GRIN2B, which is itself age-regulated.

Human Evidence (Observational)

Observational data in humans is suggestive but not interventional:

• Plasma alpha-klotho levels correlate inversely with all-cause mortality in some epidemiological cohorts of older adults
• Higher klotho levels correlate with longer telomeres
• The KL-VS genetic variant, which increases klotho expression, is associated with longer life and better cognitive function in some populations
• Higher klotho levels correlate with preserved cognitive function in patients with schizophrenia (Xiong et al., 2020)
• Lower klotho in chronic kidney disease correlates with worse cardiovascular outcomes

None of this establishes causation. The Phase 1 trials are designed to test causation.

Human Trials Underway (2025-2026)

UCSF Phase 1 (Dr. Dena Dubal): announced early 2025. The trial tests a single low-dose injection of klotho protein in healthy older adults, with cognitive function as the primary endpoint. This is the most academically rigorous program, building on the Dubal lab's preclinical work over the past decade.

Klothea Phase 1 (AKL003): announced February 2026. Klothea, spun out from Advantage Therapeutics in 2024, is developing AKL003, an alpha klotho mRNA therapy delivered via lipid nanoparticle. The randomized, double-blind, placebo-controlled trial enrolls 21 healthy adults aged 25 to 75. Primary endpoints are safety, tolerability, and biological activity (circulating alpha-klotho protein levels after repeat dosing). The trial is conducted at the GARM Clinic in Prospera, a special economic zone on the Honduran island of Roatan. Chief Science Officer Carmela Abraham described the strategy as "klotho hormone supplementation."

Minicircle plasmid gene therapy: Minicircle has been preparing a plasmid-based klotho gene therapy, with a Proof of Concept Trial planned for summer 2025 and targeted launch in 2026. Minicircle is a gene therapy platform, not a medical provider. Therapies are administered at international partner clinics outside the United States. This program is not FDA-reviewed. Minicircle has not published clinical trial data in peer-reviewed journals as of mid-2026.

Therapeutic Categories Under Investigation

Beyond longevity and cognitive function as primary endpoints, klotho is being investigated in:

• Chronic kidney disease (where klotho deficiency is a hallmark)
• Alzheimer's disease and mild cognitive impairment
• Cardiovascular disease in the elderly
• Sarcopenia
• Osteoporosis
• Osteoarthritis (a 2023 paper identified klotho involvement in knee osteoarthritis pathophysiology)

Klotho operates through several distinct, partially overlapping pathways. The most relevant mechanisms for cognitive enhancement and longevity:

FGF23 Co-receptor (the original biology)

Membrane-bound klotho forms a high-affinity complex with FGF receptor 1c (FGFR1c) and FGF23. The complex signals through canonical RAS/MAPK pathways downstream of FGFR1c activation. The primary physiological output is regulation of phosphate, vitamin D, and calcium balance. This biology is relevant to kidney and bone health but is not the main story for cognitive applications.

GRIN2B/NMDAR-Mediated Synaptic Plasticity

Soluble alpha-klotho enhances NMDA receptor signaling at glutamatergic synapses by increasing surface expression and function of the GRIN2B (NR2B) subunit. GRIN2B-containing NMDA receptors are required for hippocampal long-term potentiation (LTP), the synaptic-strengthening mechanism that underlies new memory formation.

The GRIN2B subunit declines with age in mice and humans, and pharmacological restoration of GRIN2B function rescues age-related cognitive deficits. Klotho's GRIN2B enhancement is therefore an attractive mechanism for age-related cognitive decline.

FOXO3A and Cellular Senescence

Klotho activates FOXO3A, a forkhead transcription factor strongly linked to longevity across species. FOXO3A drives expression of antioxidant enzymes (catalase, MnSOD), DNA repair genes, and senescence-resistance pathways. Higher FOXO3A activity is associated with reduced cellular senescence and reduced accumulation of senescent cells in aging tissues.

Anti-Inflammatory and Anti-Fibrotic Effects

Klotho inhibits NF-κB activation and reduces inflammatory cytokine production (IL-6, TNF-α). In animal models of chronic kidney disease, klotho replacement reduces interstitial fibrosis. In brain tissue, klotho reduces microglial activation and reactive astrogliosis.

Insulin/IGF-1 Signaling Modulation

Klotho-overexpressing mice show reduced insulin/IGF-1 signaling, a pattern repeatedly associated with extended lifespan across organisms from worms to mammals. The relationship is complex (klotho does not simply suppress these pathways) but the net effect is more consistent with the long-lived insulin-resistant phenotype than with the metabolic-syndrome insulin-resistant phenotype.

Wnt Signaling Modulation

Klotho inhibits canonical Wnt signaling. Excess Wnt signaling drives stem cell exhaustion and contributes to several aging phenotypes. This mechanism contributes to klotho's effects on tissue regeneration and stem cell maintenance.

Rodent data (preclinical, large body of literature):

• Lifespan extension 20-30% in overexpression mice
• Lifespan extension ~20% with adult-onset gene therapy
• Improved spatial memory and learning in Morris water maze
• Improved synaptic plasticity (LTP) in hippocampal slices
• Reduced amyloid pathology in some AD mouse models
• Reduced microglial activation
• Improved vascular function and reduced calcification
• Preserved muscle mass and grip strength in aged mice
• Reduced osteoarthritis severity in mouse joint injury models
• Improved kidney function in models of acute and chronic kidney injury
• Increased FOXO3A target gene expression

Human observational data:

• Higher plasma alpha-klotho correlates with better cognitive scores in older adults
• KL-VS variant carriers show better cognitive function on average
• Schizophrenia patients with higher plasma klotho have preserved cognition vs those with lower levels
• Inverse correlation with cardiovascular mortality in some cohorts
• Inverse correlation with arterial stiffness measures

Human interventional data: not yet published. Phase 1 readouts from UCSF and Klothea are anticipated in 2026-2027.

Off-label and gray-market use: a small number of users access Minicircle plasmid gene therapy at international partner clinics, primarily in Prospera (Honduras) and other special economic zones. Reported subjective effects in this population include improved sleep, cognitive sharpening, and reduced fatigue. None of this is from controlled studies, and the regulatory framework for these therapies is outside FDA review.

Preclinical mouse doses (single injection of recombinant klotho for cognitive endpoints): approximately 10 mcg/kg subcutaneously has been used in the Dubal laboratory work, with measurable cognitive effects observable hours to days after a single dose.

UCSF Phase 1 trial: low-dose single injection of klotho protein. Specific dose not publicly disclosed but described as "low dose" in trial announcements. Conservative single-dose escalation is standard for first-in-human protein therapeutics.

Klothea AKL003 mRNA: dose escalation across the 21-participant cohort, with repeat dosing of lipid nanoparticle-formulated alpha-klotho mRNA. The mRNA platform produces transient circulating klotho protein expression rather than chronic recombinant protein replacement. Specific mg/kg doses are confidential.

Minicircle plasmid gene therapy: plasmid DNA encoding klotho is injected intramuscularly. Plasmid persistence and duration of klotho expression in humans are not publicly characterized.

There is no established human dosing protocol for klotho outside these Phase 1 programs. Anyone considering klotho-based intervention outside a registered clinical trial should understand that pharmacokinetics, optimal dose, frequency, and duration are not characterized in humans.

Endogenous biology context: klotho is a naturally occurring human protein. The relevant concern is not whether the protein itself is toxic (it is not, in healthy biology) but whether exogenously elevated levels for sustained periods produce off-target effects that would not occur at normal physiological concentrations.

Theoretical concerns that require monitoring:

• Cancer risk: klotho modulates Wnt, IGF-1, and growth factor signaling. Some cancers depend on these pathways for proliferation. The relationship between klotho and cancer is complex: in some contexts klotho is a tumor suppressor (loss of klotho expression in some cancers, klotho restoration suppresses tumor growth in some models), while in others sustained growth-factor pathway modulation could affect occult malignancy. Any klotho-based intervention should not be used by people with current or recent cancer without medical monitoring.
• Phosphate and calcium disturbance: klotho is part of the FGF23 axis. Pharmacologically elevated klotho could in principle alter phosphate excretion and serum calcium. Phase 1 trial protocols include monitoring of phosphate, calcium, and FGF23 levels for this reason.
• Vitamin D metabolism: klotho regulates 1-alpha-hydroxylase. Sustained klotho elevation could alter active vitamin D levels.
• Pregnancy: no human reproductive data. Klotho is involved in placental signaling, so exposure during pregnancy is contraindicated until safety is characterized.
• Immunogenicity (recombinant protein and mRNA): any exogenous protein or mRNA platform can produce immune responses. The UCSF protein trial and Klothea mRNA trial are specifically powered to detect anti-drug antibody formation and other immune endpoints.
• Gene therapy specific concerns (Minicircle): plasmid integration risk, sustained off-target expression, lack of FDA review of the manufacturing process. The Minicircle program is conducted at international partner clinics under non-US regulatory frameworks. Informed consent in these settings is the participant's responsibility to evaluate.

No conventional adverse-event profile from controlled human trials exists yet. The first Phase 1 safety readouts are anticipated in 2026-2027.

Acute rodent safety of recombinant klotho injection is well-characterized as benign at the doses studied, with no overt toxicity in short-duration studies and no excess mortality in long-duration overexpression mice.

Klotho sits in the emerging "longevity-targeted biologic" category. The closest comparators are other interventions that target pathways linked to aging biology:

• Mots-c: a mitochondrial-derived peptide with metabolic and exercise-mimetic effects. Different mechanism (AMPK activation, metabolic gene expression), partially overlapping in the aging-biology rationale. Some Phase 1 human data.
• Humanin: another mitochondrial-derived peptide, with neuroprotective and metabolic effects. Pre-clinical evidence stronger than human evidence.
• Epitalon: a Khavinson bioregulator tetrapeptide with telomerase-modulating and pineal-stimulating activity claimed in Russian literature. Limited Western validation but decades of use in Russian gerontology research.
• SS-31 (Elamipretide): a mitochondria-targeting peptide in clinical development for Barth syndrome and other indications. Different mechanism (cardiolipin protection), different indication focus, but in the same general "longevity-mitochondrial" category.
• Senolytics (dasatinib + quercetin, fisetin): small-molecule senescent-cell clearance, complementary rather than overlapping mechanism. Klotho reduces senescence accumulation; senolytics remove existing senescent cells.
• NAD+ precursors (NMN, NR): a different aging-biology lever (mitochondrial coenzyme), with much larger consumer presence than klotho currently has. NMN and NR are already widely consumed. Klotho is not yet available outside trials and the Minicircle pathway.

Theoretical combinations:

• Klotho + NAD+ precursors: non-overlapping mechanisms (FGF23/GRIN2B vs sirtuin/NAD+). Theoretically additive but completely unstudied.
• Klotho + senolytics: non-overlapping mechanisms (senescence prevention vs senescent cell clearance). Theoretically additive but unstudied.
• Klotho + GLP-1 receptor agonists (for older adults with metabolic disease): unstudied. The cardiovascular and renal pathways of both touch some of the same biology.

Combinations to avoid until safety is characterized:

• Anyone with active or recent cancer: until the klotho-cancer relationship is better characterized in humans, klotho-based interventions outside controlled trials are not advisable in this population.
• Pregnancy or planned pregnancy: until reproductive safety data exists.
• Active gene therapy combinations: combining multiple gene therapy platforms (Minicircle klotho plus other plasmid therapies) is unstudied and the cumulative integration and immune risks are not characterized.

For informational and educational purposes only. Not medical advice. Not for human consumption unless prescribed by a licensed physician for an FDA-approved indication. Consult a qualified healthcare provider before using any peptide or pharmaceutical product.